PCH
CNTA

Polar Capital Holdings’s Centessa Pharmaceuticals CNTA Stock Holding History

Polar Capital Holdings’s Portfolio CNTA Stock Details CNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,000,000
Closed -$13.1M – 266
2025
Q2 		$13.1M Buy
+1,000,000
New +$12.7M 0.07% 172
2024
Q4 		– Sell
-640,000
Closed -$10.2M – 305
2024
Q3 		$10.2M Buy
+640,000
New +$7.84M 0.05% 203

Other funds holding CNTA

MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
IVLAV
Index Venture Life Associates VI St. Helier, Jersey $396M AUM 176.22% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Polar Capital Holdings's CNTA Position: Q3 2025 in Review

Polar Capital Holdings sold out of Centessa Pharmaceuticals (CNTA) in Q3 2025, closing a stake of 1,000,000 shares — an estimated $13.1M sold.

Polar Capital Holdings first reported a position in CNTA in Q3 2024 and held it in 2 quarters. The position peaked at $13.1M in Q2 2025. 125 funds tracked by Wall St. Rank hold CNTA as of Q3 2025.

  • Polar Capital Holdings reported no remaining Centessa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Polar Capital Holdings sold 1,000,000 Centessa Pharmaceuticals shares in Q3 2025, an estimated $13.1M.
  • Polar Capital Holdings first reported a position in Centessa Pharmaceuticals in Q3 2024 and held it in 2 quarters.
  • Polar Capital Holdings's Centessa Pharmaceuticals position peaked at $13.1M in Q2 2025.
  • 125 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q3 2025.

Based on Polar Capital Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.